SynthesisFrontiers in pharmacology2026
Neuroprotective effects and mechanistic insights of sinomenine in ischemic stroke: a systematic review and meta-analysis of preclinical animal studies.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ischemic stroke is a leading cause of long-term disability and mortality worldwide. Despite substantial advances in reperfusion therapy, effective neuroprotective strategies remain limited. Sinomenine, a bioactive alkaloid derived from plants of the Menispermaceae family, has shown neuroprotective effects in preclinical models of ischemic stroke. However, the available preclinical evidence has not been systematically quantified, and the relationship between sinomenine dosage and therapeutic efficacy remains unclear. Methods: Eight electronic databases were searched from inception to 30 March 2026. The risk of bias, reporting quality, and translational readiness were assessed using the SYRCLE risk-of-bias tool, the ARRIVE 2.0 guidelines, and the Stroke Therapy Academic Industry Roundtable criteria, respectively. Data synthesis and quantitative analyses were performed with RevMan 5.3 and Stata 17.0. Subgroup and sensitivity analyses were conducted for outcomes with high heterogeneity. Additionally, dose-response curves were fitted using restricted cubic spline models. Results: This meta-analysis included 15 studies. In animal models of ischemic stroke, sinomenine significantly reduced cerebral infarct volume, improved neurological function score (NFS), and preserved blood-brain barrier (BBB) integrity. Sinomenine also downregulated neuroinflammation-related biomarkers, enhanced superoxide dismutase (SOD) activity, and modulated apoptosis-related marker levels. RCS analysis suggested nonlinear dose-response relationships between sinomenine dosage and cerebral infarct volume, NFS, and brain water content. Subgroup analyses revealed that animal strain, comorbidity status, experimental blinding, drug dosage, and timing of administration may influence effect sizes. Trim-and-fill analysis showed that the pooled standardized mean difference (SMD) for cerebral infarct volume attenuated from -3.02 (95% CI [-3.96, -2.08]) to -1.97 (95% CI [-2.93, -1.01]) after adjustment, whereas that for NFS attenuated from -1.57 (95% CI [-2.18, -0.97]) to -1.06 (95% CI [-1.72, -0.40]). Conclusion: In animal models, sinomenine may mitigate ischemic stroke injury through multiple pathways, with the efficacy following nonlinear dose-response relationships, suggesting its potential as an adjunctive neuroprotective intervention warranting further investigation. However, given the methodological limitations of the included studies, these findings should be interpreted cautiously. To facilitate clinical translation, future studies should incorporate more rigorous and standardized experimental designs to strengthen the evidence base and validate its therapeutic potential. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261359581, identifier CRD420261359581.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.